Model for end-stage liver disease (MELD) exception guidelines: Results and recommendations from the MELD exception study group and conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula

被引：116

作者：

Freeman, Richard B., Jr.

Gish, Robert G.

Harper, Ann

Davis, Gary L.

Vierling, John

Lieblein, Leslie

Klintmalm, Goran

Blazek, Jamie

Hunter, Robert

Punch, Jeffrey

机构：

[1] Calif Pacific Med Ctr, Dept Med, San Francisco, CA 94115 USA

[2] Calif Pacific Med Ctr, Dept Transplantat, San Francisco, CA 94115 USA

[3] Calif Pacific Med Ctr, Div Hepatol & Complex GI, Phys Fdn, San Francisco, CA 94115 USA

[4] Tufts Univ, New England Med Ctr, Dept Surg, Div Transplantat, Boston, MA 02111 USA

[5] United Network Organ Sharing, Richmond, VA USA

[6] Baylor Univ, Med Ctr, Baylor Reg Transplant Inst, Dallas, TX USA

[7] Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA 90024 USA

[8] Ochsner Multi Organ Transplant Ctr, New Orleans, LA USA

[9] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA

来源：

LIVER TRANSPLANTATION | 2006年 / 12卷 / 12期

关键词：

WAITING-LIST; HEPATOCELLULAR-CARCINOMA; MORTALITY; SURVIVAL; POLICY;

D O I：

10.1002/lt.20979

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

[No abstract available]

引用

页码：S128 / S136

页数：9

共 27 条

[1] Model for end-stage liver disease (MELD) exception for polycystic liver disease [J].

Arrazola, Luis ;

Moonka, Dilip ;

Gish, Robert G. ;

Everson, Gregory T. .

LIVER TRANSPLANTATION, 2006, 12 (12) :S110-S111

[2] Serum sodium predicts mortality in patients listed for liver transplantation [J].

Biggins, SW ;

Rodriguez, HJ ;

Bacchetti, P ;

Bass, NM ;

Roberts, JP ;

Terrault, NA .

HEPATOLOGY, 2005, 41 (01) :32-39

[3]

BIGGINS SW, 2006, IN PRESS LIVER TRANS

[4] Predicting the probability of progression-free survival in patients with small hepatocellular carcinoma [J].

Cheng, SJ ;

Freeman, RB ;

Wong, JB .

LIVER TRANSPLANTATION, 2002, 8 (04) :323-328

[5] Model for end-stage liver disease (MELD) exception for hepatopulmonary syndrome [J].

Fallon, Michael B. ;

Mulligan, David C. ;

Gish, Robert G. ;

Krowka, Michael J. .

LIVER TRANSPLANTATION, 2006, 12 (12) :S105-S107

[6] The new liver allocation system: Moving toward evidence-based transplantation policy [J].

Freeman, RB ;

Wiesner, RH ;

Harper, A ;

McDiarmid, SV ;

Lake, J ;

Edwards, E ;

Merion, R ;

Wolfe, R ;

Turcotte, J ;

Teperman, L .

LIVER TRANSPLANTATION, 2002, 8 (09) :851-858

[7] Waiting list removal rates among patients with chronic and malignant liver diseases [J].

Freeman, RB ;

Edwards, EB ;

Harper, AM .

AMERICAN JOURNAL OF TRANSPLANTATION, 2006, 6 (06) :1416-1421

[8] MELD and the quality of life [J].

Freeman, RB .

LIVER TRANSPLANTATION, 2005, 11 (02) :134-136

[9] Mortality risk versus other endpoints: Who should come first on the liver transplant waiting list? [J].

Freeman, RB .

LIVER TRANSPLANTATION, 2004, 10 (05) :675-677

[10] Model for end-stage liver disease (MELD) exception for bacterial cholangitis [J].

Gores, Gregory J. ;

Gish, Robert G. ;

Shrestha, Roshan ;

Wiesner, Russell H. .

LIVER TRANSPLANTATION, 2006, 12 (12) :S91-S92

← 1 2 3 →